Vinci Pharmaceuticals Closes Over $8 Million Series A Financing to Develop EPIPLANT™ Drug Delivery Platform
Vinci Pharmaceuticals Inc. has completed an over $8 million Series A financing round, bringing its total funding to more than $16.5 million when combined with a previous Seed round of $8.5 million. The funds will support GMP manufacturing, testing activities, and the upcoming first-in-human Phase 1/2a clinical study for EPIPLANT™ in 2027. EPIPLANT™ is Vinci’s proprietary episcleral sustained-release drug delivery platform designed to overcome limitations of intraocular injections by delivering drugs directly to retinal tissues. The technology was developed under the leadership of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest in Dallas. The financing round was led by Dynagrow Capital with support from MintPharma Capital. Vinci aims to reduce treatment burden for patients through its needle-free delivery system that can accommodate a range of active pharmaceutical ingredients.
Tickers: $VINP
Topics: Biotech Drug Delivery Systems Ophthalmology Pharmaceuticals